STAT3 mediated the isoleucine-induced Alzheimer’s disease progression
Brain Research · 2026-10 · 1889 · 150472
DOI: 10.1016/j.brainres.2026.150472 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Research, 2026-10. Verfasst von Yu Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Shandong Center of Technology Innovation for Molecular Targeting and Intelligent Diagnosis and Treatment, Shandong Medical and Ph…. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Alzheimer Disease, Isoleucine. Die Arbeit nennt 72 Literaturangaben. Gefördert von: Key Technology Research and Development Program of Shandong, National Natural Science Foundation of China.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is a neurodegenerative disorder that significantly impacts millions globally, with rising prevalence among the aging population, emphasizing the need for effective interventions. Isoleucine, a branched-chain amino acid, crosses the blood-brain barrier and plays a role in various neurological disorders. In this study, we investigated the association of isoleucine with AD traits using the BXD mouse reference population, revealing significant correlations with Y-maze performance, anxiety assays, contextual fear conditioning, and the age of onset for working memory deficits. In vitro, exogenous isoleucine supplementation in HT22 and PC12 cells increased amyloid precursor protein (APP) and phosphorylated tau (p-tau) levels. Subsequent analysis identified 2,000 probes correlated with isoleucine and revealed STAT3 as a candidate downstream regulator. Overexpression of STAT3 increased APP and p-tau levels, and STAT3 inhibition abolished this effect, suggesting that isoleucine modulates AD progression via STAT3 activation. Mendelian randomization analysis further supported a causal relationship between elevated isoleucine levels and AD risk. This work provides insights into isoleucine as a potential risk factor for AD and identifies STAT3 as a mediator of isoleucine-related AD susceptibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Shandong Center of Technology Innovation for Molecular Targeting and Intelligent Diagnosis and Treatment, Shandong Medical and Pharmaceutical University, Yantai, China.
- Department of Gastroenterology, Hebei Petrochina Central Hospital, Langfang, China.
- The Second School of Clinical Medicine, Shandong Medical and Pharmaceutical University, Yantai, China.
- Department of Genetics, Genomics and Informatics, University of Tennessee Health Science Center, Memphis, USA.
- The First School of Clinical Medicine, Shandong Medical and Pharmaceutical University, Yantai, China.
- School of Pharmacy, Shandong Center of Technology Innovation for Molecular Targeting and Intelligent Diagnosis and Treatment, Shandong Medical and Pharmaceutical University, Yantai, China. Electronic address: xufuyiphd@…
Förderung
- Key Technology Research and Development Program of Shandong
- National Natural Science Foundation of China
Zitieren
APA
Liu, Y., Li, Y., Zhou, Y., Hei, Y., Wang, S., Bajpai, A. K., Chang, X., Wang, X., Xu, F., & Yao, C. (2026). STAT3 mediated the isoleucine-induced Alzheimer’s disease progression. Brain Research, 1889, 150472. https://doi.org/10.1016/j.brainres.2026.150472
Vancouver
Liu Y, Li Y, Zhou Y, Hei Y, Wang S, Bajpai AK, et al. STAT3 mediated the isoleucine-induced Alzheimer’s disease progression. Brain Research. 2026;1889:150472. doi:10.1016/j.brainres.2026.150472
BibTeX
@article{Liu2026,
author = {Liu, Yu and Li, Yuhe and Zhou, Yanjun and Hei, Yu and Wang, Shujing and Bajpai, Akhilesh Kumar and Chang, Xueying and Wang, Xinhao and Xu, Fuyi and Yao, Cuifang},
title = {STAT3 mediated the isoleucine-induced Alzheimer’s disease progression},
journal = {Brain Research},
year = {2026},
volume = {1889},
pages = {150472},
doi = {10.1016/j.brainres.2026.150472}
}
EUVIMED